News
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...
Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, ...
Sarepta (SRPT) shared updates from its clinical programs focused on limb-girdle muscular dystrophy subtypes 2C/R5, 2D/R3, and 2E/R4. Following ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates ...
William Blair analyst Sami Corwin maintained a Hold rating on Applied Therapeutics (APLT – Research Report) today. The company’s shares closed ...
The law firm of Kessler Topaz Meltzer & Check, LLP ( is currently investigating potential violations of the federal ...
We recently published a list of 11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts. In this article, we are ...
Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...
Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Sarepta (SRPT) to $182 from $196 and keeps an Overweight rating on the ...
Morgan Stanley analyst Michael Ulz maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...
In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), with a ...
In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Alnylam Pharma (ALNY – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results